|
Autistic Disorder
|
0.320 |
Biomarker
|
disease |
BEFREE |
This will include the (1) DRD4 gene associated with attentiondeficit/ hyperactivity disorder, located in a locus that underwent a positive selection; the (2) GABRB2 gene, a gene associated with schizophrenia and recently reported as the target of a positive selection; (3) MARK1, a candidate gene for autism that was reported as displaying a signature of adaptative evolution in the human lineage, and (4) the ADH and ALDH2 genes which are associated with alcoholism, and for which evidence of positive selection was identified in the human lineage since the divergence between humans and chimpanzees.
|
20166940 |
2010 |
|
Autistic Disorder
|
0.320 |
Biomarker
|
disease |
CTD_human |
High-resolution single-nucleotide polymorphisms (126 SNPs) genotyping across the chromosome 1q41-q42 region, followed by a MARK1 (microtubule affinity-regulating kinase 1)-tagged-SNP association study in 276 families with autism from the Autism Genetic Research Exchange, showed that several SNPs within the MARK1 gene were significantly associated with ASDs by transmission disequilibrium tests.
|
18492799 |
2008 |
|
Autistic Disorder
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
High-resolution single-nucleotide polymorphisms (126 SNPs) genotyping across the chromosome 1q41-q42 region, followed by a MARK1 (microtubule affinity-regulating kinase 1)-tagged-SNP association study in 276 families with autism from the Autism Genetic Research Exchange, showed that several SNPs within the MARK1 gene were significantly associated with ASDs by transmission disequilibrium tests.
|
18492799 |
2008 |
|
Autistic Disorder
|
0.320 |
AlteredExpression
|
disease |
LHGDN |
High-resolution single-nucleotide polymorphisms (126 SNPs) genotyping across the chromosome 1q41-q42 region, followed by a MARK1 (microtubule affinity-regulating kinase 1)-tagged-SNP association study in 276 families with autism from the Autism Genetic Research Exchange, showed that several SNPs within the MARK1 gene were significantly associated with ASDs by transmission disequilibrium tests.
|
18492799 |
2008 |
|
Malignant neoplasm of stomach
|
0.300 |
Biomarker
|
disease |
CTD_human |
Methylation status of the 32 randomly selected and 16 potential tumor-related genes was analyzed in 10 primary gastric cancers, and 42 genes (ABHD9, ADFP, ALDH1A3, ANXA5, AREG, BDNF, BMP7, CAV1, CDH2, CLDN3, CTSL, EEF1A2, F2R, FADS1, FSD1, FST, FYN, GPR54, GREM1, IGFBP3, IGFBP7, IRS2, KISS1, MARK1, MLF1, MSX1, MTSS1, NT5E, PAX6, PLAGL1, PLAU, PPIC, RBP4, RORA, SCRN1, TBX3, TFAP2C, TNFSF9, ULBP2, WIF1, ZNF177 and ZNF559) were methylated in at least one primary gastric cancer.
|
16367923 |
2006 |
|
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
|
16367923 |
2006 |
|
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray.
|
16367923 |
2006 |
|
Gastric Adenocarcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Ovarian Serous Adenocarcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Alzheimer's Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
The structure highlights the kinase-specific autoinhibitory binding modes of different KA1 domains, and provides potential new avenues by which to intervene therapeutically in Alzheimer's disease and cancers in which MARK1 or related kinases are implicated.
|
30099988 |
2018 |
|
Alzheimer's Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
These efforts allowed for the identification of a compound with properties suitable for use as an in vitro tool compound for validation studies on MARK as a viable target for Alzheimer's disease.
|
27816515 |
2017 |
|
Alzheimer's Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
Attempts to optimize pharmacokinetic properties in a promising series of pyrrolopyrimidinone MARK inhibitors for the treatment of Alzheimer's disease are described.
|
27894874 |
2017 |
|
Alzheimer's Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
Finally, we review the connections between disruptions in PAR-1/MARK function and Alzheimer's disease and cancer.
|
28236972 |
2017 |
|
Alzheimer's Disease
|
0.060 |
Biomarker
|
disease |
BEFREE |
These results suggest that stabilization of microtubule-unbound tau by phosphorylation at Ser262/356 via the PAR-1/MARK may act in the initial steps of tau mismetabolism in AD pathogenesis, and that such tau species may represent a potential therapeutic target for AD.
|
27023670 |
2016 |
|
Schizophrenia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Fragility of early visual percepts appears to mark genetic liability specific to schizophrenia and may serve as an endophenotype for the disorder.
|
22446567 |
2013 |
|
Alzheimer's Disease
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
In a group of 729 Spanish late-onset AD patients and 670 healthy controls, we examined variations into a set of 20 candidate genes of kinases involved in tau phosphorylation at AD-related sites (PRKACB; CAMK2A; MARK1, 2, 3 and 4; CSNK1D; CDC2; RPS6KB1 and 2; p38α and β; IB1; JNK1, 2 and 3; MEK1 and 2; ERK1 and 2), to address hypotheses of genetic variation that might influence both AD risk and age at disease onset.
|
21811019 |
2011 |
|
Schizophrenia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Although errant saccadic eye movements may mark genetic factors in schizophrenia, little is known about abnormal brain activity that precedes saccades in individuals with genetic liability for schizophrenia.
|
20636287 |
2011 |
|
Schizophrenia
|
0.060 |
Biomarker
|
disease |
BEFREE |
This will include the (1) DRD4 gene associated with attentiondeficit/ hyperactivity disorder, located in a locus that underwent a positive selection; the (2) GABRB2 gene, a gene associated with schizophrenia and recently reported as the target of a positive selection; (3) MARK1, a candidate gene for autism that was reported as displaying a signature of adaptative evolution in the human lineage, and (4) the ADH and ALDH2 genes which are associated with alcoholism, and for which evidence of positive selection was identified in the human lineage since the divergence between humans and chimpanzees.
|
20166940 |
2010 |
|
Schizophrenia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
There is considerable evidence that schizophrenia spectrum personality (SSP) disorders mark genetic risk for schizophrenia.
|
14552505 |
2003 |
|
Schizophrenia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Smooth-pursuit dysfunction may mark genetic vulnerability that is relatively specific to schizophrenia.
|
12892855 |
2003 |
|
Schizophrenia
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Spatial working memory impairments are among the neurocognitive deficits that may mark genetic predisposition toward schizophrenia.
|
12679242 |
2003 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Overexpression of MARK1 could partly reverse the cancer-promoting function of miR-23a.
|
31281935 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Overexpression of MARK1 could partly reverse the cancer-promoting function of miR-23a.
|
31281935 |
2019 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Finally, we review the connections between disruptions in PAR-1/MARK function and Alzheimer's disease and cancer.
|
28236972 |
2017 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
The results showed that inhibiting LKB1 or MARK1 in NSCLC increases the collagen fiber alignment and captures outward alignment vectors from the tumor spheroid, corresponding to high invasiveness of LKB1 mutant cancer cells.
|
28045069 |
2017 |